2023
Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831
Lo A, Lee I, Pei Q, Wu Y, McCarten K, Hoppe B, Hodgson D, Roberts K, Milgrom S, Kessel S, Cole P, Kelly K, Cho S. Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. Pediatric Blood & Cancer 2023, 70: e30452. PMID: 37243975, PMCID: PMC10546608, DOI: 10.1002/pbc.30452.Peer-Reviewed Original ResearchConceptsRelapse-free survivalLarge mediastinal adenopathySlow early responseInferior relapse-free survivalWorse relapse-free survivalMediastinal mass ratioPediatric Hodgkin lymphomaHodgkin's lymphomaMediastinal adenopathyPrognostic valueAdvanced-stage HL patientsChildren's Oncology Group studyChest X-rayHazard ratioHL patientsMedian agePoor prognosisChest radiographsMass volumeMass diameterPatientsML/Group studyCTEarly response
2020
Prognostic Value of Chest X-ray and CT Defined Large Mediastinal Adenopathy in High Risk Pediatric Hodgkin Lymphoma (COG AHOD0831)
Lo A, Lee I, Pei Q, McCarten K, Hoppe B, Hodgson D, Roberts K, Milgrom S, Kelly K, Cho S. Prognostic Value of Chest X-ray and CT Defined Large Mediastinal Adenopathy in High Risk Pediatric Hodgkin Lymphoma (COG AHOD0831). International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s177-s178. DOI: 10.1016/j.ijrobp.2020.07.959.Peer-Reviewed Original ResearchPediatric Hodgkin lymphomaChest X-rayLarge mediastinal adenopathyMediastinal adenopathyHodgkin's lymphomaPrognostic value
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities
1999
135 Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Vermont C, Rizzeri D, Clough R, Prosnitz L. 135 Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 216. DOI: 10.1016/s0360-3016(99)90153-0.Peer-Reviewed Original Research